International Clinical Trial: Topical Boswellia Serrata 2% to Prevent Radiation Dermatitis in Head and Neck Cancer

Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07778290) titled 'Topical Boswellia Serrata 2% to Prevent Radiation Dermatitis in Head and Neck Cancer' on Aug. 18.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).

Primary Sponsor: Youssef Hashem Hafez

Condition: Head and Neck Neoplasms Radiodermatitis

Intervention: Drug: Boswellia serrata 2% topical cream

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: August 18, 2026

Target Sample Size: 60

Countries of Recruitment: Egypt

To know more, visit https://clinicaltrials.gov/study/NCT0777...